Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model

Pharmaceutical Research

Volumn 33, Issue 11, 2016, Pages 2604-2616

  Edwards, Chris D ^a   Luscombe, Chris ^a   Eddershaw, Peter ^a   Hessel, Edith M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

intratracheal delivery; isolated perfused lung; physicochemical properties; pulmonary absorption; quantitative structure activity relationship model

Indexed keywords

AMBROXOL; AMILORIDE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; INDACATEROL; IPRATROPIUM BROMIDE; LIDOCAINE; MONTELUKAST; NEDOCROMIL; SALBUTAMOL; SALMETEROL; TACROLIMUS; ZANAMIVIR; DRUG; ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; ISOLATED PERFUSED RESPIRING RAT LUNG MODEL; LIMIT OF DETECTION; LIPOPHILICITY; LUNG ABSORPTION; LUNG FUNCTION; LUNG MODEL; MALE; NONHUMAN; PERMEABILITY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SURFACE AREA; TANDEM MASS SPECTROMETRY; TOTAL POLAR SURFACE AREA; ANIMAL; BIOLOGICAL MODEL; BREATHING; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; LUNG; METABOLISM; MOLECULAR MODEL; PARTICLE SIZE; PHYSIOLOGY; RESPIRATORY FUNCTION; SURFACE PROPERTY;

ANIMALS; DRUG DISCOVERY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IONS; LUNG; MALE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RESPIRATION; RESPIRATORY TRACT ABSORPTION; SURFACE PROPERTIES;

EID: 84978079796     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1983-4     Document Type: Article

References (44)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.
2. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem. 2008;51(4):817–34.
3. Ritchie TJ, Macdonald SJ. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14(21–22):1011–20.
4. Young RJ, Green DV, Luscombe CN, Hill AP. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today. 2011;16(17–18):822–30.
5. Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett. 2008;18(17):4872–5.
6. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6(11):881–90.
7. Price DA, Blagg J, Jones L, Greene N, Wager T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol. 2009;5(8):921–31.
8. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10(3):197–208.
9. Matero S, Lahtela-Kakkonen M, Korhonen O, Ketolainen J, Lappalainen R, Poso A. Chemical space of orally active compounds. Chemom Intell Lab Syst. 2006;84(1–2):134–41.
10. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53(3):1098–108.
11. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.
12. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med. 1994;7(1):49–75.
13. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
14. Chan TL, Lee PS, Hering WE. Deposition and clearance of inhaled diesel exhaust particles in the respiratory tract of Fischer rats. 1981;1(2):77–82.
15. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19(1):3–36.
16. Enna SJ, Schanker LS. Absorption of saccharides and urea from the rat lung. Am J Physiol. 1972;222(2):409–14.
17. Henderson RF, Bechtold WE, Medinsky MA, Fischer JP, Lee TT. The effect of molecular weight/lipophilicity on clearance of organic compounds from lungs. Toxicol Appl Pharmacol. 1988;95(3):515–21.
18. Ritchie TJ, Luscombe CN, Macdonald SJ. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J Chem Inf Model. 2009;49(4):1025–32.
19. Byron PR, Niven RW. A novel dosing method for drug administration to the airways of the isolated perfused rat lung. J Pharm Sci. 1988;77(8):693–5.
20. Jeppsson AB, Nilsson E, Waldeck B. Formoterol and salmeterol are both long acting compared to terbutaline in the isolated perfused and ventilated guinea-pig lung. Eur J Pharmacol. 1994;257(1–2):137–43.
21. Mehendale HM, Angevine LS, Ohmiya Y. The isolated perfused lung—a critical evaluation. Toxicology. 1981;21(1):1–36.
22. Ryrfeldt A, Persson G, Nilsson E. Pulmonary disposition of the potent glucocorticoid budesonide, evaluated in an isolated perfused rat lung model. Biochem Pharmacol. 1989;38(1):17–22.
23. Tronde A, Krondahl E, von Euler-Chelpin H, Brunmark P, Bengtsson UH, Ekstrom G, et al. High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery. Peptides. 2002;23(3):469–78.
24. Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernas H, et al. Drug absorption from the isolated perfused rat lung—correlations with drug physicochemical properties and epithelial permeability. J Drug Target. 2003;11(1):61–74.
25. Selg E, Ewing P, Acevedo F, Sjoberg CO, Ryrfeldt A, Gerde P. Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. J Aerosol Med Pulm Drug Deliv. 2013;26(4):181–9.
26. Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976;11(1):13–33.
27. Fisher AB, Dodia C, Linask J. Perfusate composition and edema formation in isolated rat lungs. Exp Lung Res. 1980;1(1):13–21.
28. Geladi P, Kowalski BR. Partial least-squares regression: a tutorial. Anal Chim Acta. 1986;185:1–17.
29. Wold S, Geladi P, Esbensen K, Öhman J. Multi-way principal components-and PLS-analysis. J Chemom. 1987;1(1):41–56.
30. Platts JA, Abraham MH, Butina D, Hersey A. Estimation of molecular linear free energy relationship descriptors by a group contribution approach. 2. prediction of partition coefficients. J Chem Inf Model. 2000;40(1):71–80.
31. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Scieszka JF. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res. 1989;6(1):71–7.
32. Valko K, Bevan C, Reynolds D. Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log P/log D. Anal Chem. 1997;69(11):2022–9.
33. Andrews PR, Craik DJ, Martin JL. Functional group contributions to drug-receptor interactions. J Med Chem. 1984;27(12):1648–57.
34. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43(20):3714–7.
35. Gupta SV, Gupta D, Sun J, Dahan A, Tsume Y, Hilfinger J, et al. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm. 2011;8(6):2358–67.
36. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3–29.
37. Jones RM, Harrison A. A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Xenobiotica. 2012;42(1):75–85.
38. Baumann D, Bachert C, Hogger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540–50.
39. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2):660–8.
40. Al-Jayyoussi G, Price DF, Francombe D, Taylor G, Smith MW, Morris C, et al. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. J Pharm Sci. 2013;102(9):3382–94.
41. Bosquillon C. Drug transporters in the lung—do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci. 2010;99(5):2240–55.
42. Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A, Francombe D, Kreitmeyr K, Morris CJ. Spatial expression and functionality of drug transporters in the intact lung. Object Further Res. 2011;63(1–2):110–8.
43. Gnadt M, Trammer B, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, et al. Comparison of the bronchodilating effects of inhaled beta(2)-agonists after methacholine challenge in a human lung reperfusion model. Eur J Pharm Biopharm. 2012;81(3):617–26.
44. Gnadt M, Trammer B, Freiwald M, Kardziev B, Bayliss MK, Edwards CD, et al. Methacholine delays pulmonary absorption of inhaled beta(2)-agonists due to competition for organic cation/carnitine transporters. Pulm Pharmacol Ther. 2012;25(1):124–34.